Trending Stories on Eyewire+

Alcon Announces US Launch of Voyager DSLT for Glaucoma and Ocular Hypertension

Alcon announced the full US?commercial availability of Voyager?DSLT, the first and only direct selective laser trabeculoplasty device (DSLT). According to Alcon, Voyager DSLT may?accelerate the adoption of laser as a first-line therapy, making the treatment?availability for more patients. Read More

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa

Glaukos?announced it has received notification from the FDA?acknowledging the previously submitted new drug application (NDA) for Epioxa?(Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus. The FDA stated that the NDA?is sufficiently complete to permit a substantive review. Read More

Opthea Treats Final Patient in Phase 3 COAST Trial for Wet AMD

Opthea?announced that it has completed the final week 52 patient visit in COAST, the first of two phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatment of wet AMD. The topline results from both trials are anticipated in early Q2 CY25 (COAST) and mid-CY25 (ShORe). Read More

EyewireTV | 2.19.2025

Alcon launches the first DSLT device in thee US; thee FDA approves an expanded label for Astellas Pharma's?geographic atrophy drug Izervay; and New World Medical receives FDA clearance?for the VIA360?Surgical System.?Click here to check it out!

Latest In Podcasts

Beware the Dry Eye Masqueraders

Catherine Nelson, MD, MPH , recaps her article, “Impact of Selective Laser Trabeculoplasty on Diurnal IOP Fluctuation,” which was written with Barbara Wirostko, MD, FARVO, and featured in the November/December issue of?Glaucoma Today. Home tonometry data are shedding light on SLT’s effect on IOP spikes in the months following laser treatment. This article reviews diurnal IOP fluctuation before and after SLT and discusses the implications of home tonometry in research. Click here to catch the latest episode.

Marc R. Bloomenstein, OD, FAAO, invites Steven Ferrucci, OD, FAAO, to discuss the role of optometrists in diagnosing and referring patients with geographic atrophy, diabetic retinopathy, and other retinal conditions. They will also discuss the integration of artificial intelligence and at-home monitoring technology to help manage these patients. Click here to catch the latest episode.

Eyewire News: The Podcast

The AAO responds to a proposal by the NIH to limit indirect funding for research projects; Lumenis launches a new device to address lower lid laxity and impaired blinking; and AI Optics receives FDA clearance for a?handheld retinal imaging system. Catch the latest episodes here!

Latest in Subspecialties:

CATARACT: MyEyeDr. Partners with CoFi to Streamline Patient Payments

REFRACTIVE: Cost, Purchase Factors, and Correct Usage Drive Online Contact Lens Searches

GLAUCOMA: Seonix Bio Launches SightScore, the First Clinical Polygenic Risk Score Test for Glaucoma in the US

RETINA: World’s First AI-Powered Cardiovascular Retinal Screening to be Launched in the UK

OPTOMETRY: Mount Sinai Team Identifies Underlying Mechanisms of Age-Related Meibomian Gland Dysfunction, Possible Treatment Options for Dry Eye Disease

Thank you for reading! We'll be back next week with another edition of?Eyewire+ Weekly Digest. For the most up to date news, please visit us at Eyewire+.